Tiotropium Bromide

Producers shown on SFDA

(Record date:18/10/2021）

Producers shown on EP

(Quoted from EP website；record date:18/10/2021）

Producer:Zhejiang Xianju Pharmaceutical Co., Ltd., formerly known as Xianju pharmaceutical factory, was founded in 1972. It is a professional manufacturer of steroidal drugs in China. The total share capital of the company is 916212166 yuan, covering an area of 650 mu. At present, it has more than 3900 employees, including 15 technical personnel and 35 sales personnel. It is a comprehensive manufacturer of APIs and preparations.

The company has nearly 200 varieties and has a production capacity of 300 tons of API, 10 billion tablets, 500 million capsules, 500 million water needles, 20 million lyophilized powder injections, 35 million creams and 60 million bags of granules.

At present, all products of the company have passed the national GMP certification. 13 products such as vecuronium, prednisone acetate, prednisolone and medroxyprogesterone acetate have been certified by FDA; Nine products including cyproterone acetate, prednisolone and norethisterone have obtained the EU CEP certificate; Prednisolone, betamethasone dipropionate and betamethasone valerate have passed the KFDA certification in Korea; Small volume injection production line and comprehensive solid preparation production line (I) have passed the invima certification in Colombia.

Staff size:About 4000 persons

Registered capital:RMB 989 million 200 thousand

Producer:Nanchang Hongyi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Nanchang Hongyi Technology Co., Ltd., was established in 2002. It is mainly engaged in the R & D, production and sales of new drugs. It has established a drug research institute, engineering technology center and GMP production workshops for chemical synthesis, traditional Chinese medicine extraction, tablets, capsules, granules, dry suspensions, dropping pills and powder sprays.

Staff size:100-199 persons

Registered capital:RMB 30 million

At present, the company has 7 product production workshops, 4 pilot workshops for new products, 1 product development center, and 2 drug inspection centers, power workshops and warehouses. There are 52 products approved for listing in China, of which 16 are listed as high-tech products in Jiangsu Province, involving liver disease, tumor, cardiovascular, respiratory and other fields, with an annual production capacity of more than 100 tons.

With the continuous increase of product types and production scale, the economic benefits of the company have also increased year by year. In 2020, the sales revenue will reach 3.5 billion yuan, including 10 API products such as arotinib hydrochloride, magnesium isoglycyrrhizinate and Diammonium Glycyrrhizinate, forming a "product group with sales of more than 100 million". The company has passed FDA certification for "zero defect" twice, and 14 products passed GMP on-site inspection in 2020, indicating that the company's quality management is at a high level in the industry.

Staff size:1000-1999 persons

Registered capital:RMB 103 million 528 thousand and 805